SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:lnu-41969"
 

Sökning: onr:"swepub:oai:DiVA.org:lnu-41969" > Low Rates of Both L...

Low Rates of Both Lipid-Lowering Therapy Use and Achievement of Low-Density Lipoprotein Cholesterol Targets in Individuals at High-Risk for Cardiovascular Disease across Europe

Halcox, Julian P. (författare)
Swansea University College of Medicine, UK
Tubach, Florence (författare)
INSERM, France ; Paris Diderot University, France
Lopez-Garcia, Esther (författare)
Universidad Autónoma de Madrid, Spain ; CIBERESP, Spain
visa fler...
De Backer, Guy (författare)
University of Ghent, Belgium
Borghi, Claudio (författare)
University of Bologna, Italy
Dallongeville, Jean (författare)
Université Lille-Nord de France, France
Guallar, Eliseo (författare)
Johns Hopkins Bloomberg School of Public Health, USA ; National Center for Cardiovascular Research, Spain
Medina, Jesús (författare)
AstraZeneca Farmacéutica Spain, Spain
Perk, Joep (författare)
Linnéuniversitetet,Institutionen för hälso- och vårdvetenskap (HV)
Sazova, Oguen (författare)
AstraZeneca Global Medical Affairs, UK
Sweet, Stephen (författare)
Oxford PharmaGenesis Ltd, UK
Roy, Carine (författare)
INSERM, France ; Hôpital Bichat-Claude Bernard, France
Banegas, José R. (författare)
Universidad Autónoma de Madrid, Spain ; CIBERESP, Spain
Rodriguez-Artalejo, Fernando (författare)
Universidad Autónoma de Madrid, Spain ; CIBERESP, Spain
visa färre...
 (creator_code:org_t)
2015
2015
Engelska.
Ingår i: PLoS ONE. - 1932-6203 .- 1932-6203. ; 10:2
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Aims To analyse the treatment and control of dyslipidaemia in patients at high and very high cardiovascular risk being treated for the primary prevention of cardiovascular disease (CVD) in Europe. Methods and Results Data were assessed from the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA, ClinicalTrials.gov identifier: NCT00882336), which included a randomly sampled population of primary CVD prevention patients from 12 European countries (n = 7641). Patients' 10-year risk of CVD-related mortality was calculated using the Systematic Coronary Risk Evaluation (SCORE) algorithm, identifying 5019 patients at high cardiovascular risk (SCORE >= 5% and/or receiving lipid-lowering therapy), and 2970 patients at very high cardiovascular risk (SCORE >= 10% or with diabetes mellitus). Among high-risk individuals, 65.3% were receiving lipid-lowering therapy, and 61.3% of treated patients had uncontrolled low-density lipoprotein cholesterol (LDL-C) levels (>= 2.5 mmol/L). For very-high-risk patients (uncontrolled LDL-C levels defined as >= 1.8 mmol/L) these figures were 49.5% and 82.9%, respectively. Excess 10-year risk of CVD-related mortality (according to SCORE) attributable to lack of control of dyslipidaemia was estimated to be 0.72% and 1.61% among high-risk and very-high-risk patients, respectively. Among high-risk individuals with uncontrolled LDL-C levels, only 8.7% were receiving a high-intensity statin (atorvastatin >= 40 mg/day or rosuvastatin >= 20 mg/day). Among very-high-risk patients, this figure was 8.4%. Conclusions There is a considerable opportunity for improvement in rates of lipid-lowering therapy use and achievement of lipid-level targets in high-risk and very-high-risk patients being treated for primary CVD prevention in Europe.

Ämnesord

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Hematology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Hematologi (hsv//swe)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)

Nyckelord

Hälsovetenskap
Health and Caring Sciences

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

  • PLoS ONE (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy